Staar Surgical Co income statement

In fiscal 2025, Staar Surgical Co reported revenue of $239m, down 23.7% on the year before, operating income of −$91.7m (a -38.3% margin) and net income of −$80.4m, or −$1.62 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Staar Surgical Co: income statement, annual
Fiscal year	2009Jan 2010	2010Dec 2010	2011Dec 2011	2012Dec 2012	2013Jan 2014	2014Jan 2015	2015Jan 2016	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Jan 2020	2020Jan 2021	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Jan 2026	LTMJul 2026
Revenue	51	55	63	64	72	75	77	82	91	124	150	163	230	239	322	314	239	340
Cost of revenue	20	20	20	19	22	26	24	24	26	32	38	45	52	61	70	74	57	79
Gross profit	31	35	42	44	50	49	53	58	64	92	112	118	179	223	253	240	182	260
Research and development	6	6	6	6	7	12	15	21	20	22	25	32	34	36	40	45	40	38
Selling, general and administrative	—	—	—	—	—	—	—	71	68	85	100	112	145	180	225	252	274	246
Selling and marketing	15	17	18	21	24	26	24	—	—	—	—	—	—	—	—	—	—	—
General and administrative	15	15	15	15	17	18	20	—	—	—	—	—	—	—	—	—	—	—
Operating income	−5	−3	3	−1	1	−8	−5	−13	−4	7	12	7	33	44	28	−13	−92	14
Interest expense	1	1	1	0	0	0	0	0	0	—	—	—	—	—	—	—	—	—
Income before tax	−6	−4	3	−1	1	−9	−6	−12	−2	7	13	8	31	46	34	−9	−82	17
Income tax	1	0	1	1	1	−0	1	−0	−0	2	−1	2	4	6	12	11	−2	14
Net income	−6	0	1	−2	0	−8	−7	−12	−2	5	14	6	28	40	21	−20	−80	4
Diluted EPS	−$0.19	$0.00	$0.04	−$0.05	$0.01	−$0.22	−$0.17	−$0.30	−$0.05	$0.11	$0.30	$0.12	$0.56	$0.80	$0.43	−$0.41	−$1.62	$0.08
Diluted shares (average)	32m	35m	37m	36m	39m	38m	39m	40m	41m	45m	47m	48m	49m	49m	49m	49m	50m	50m
EBITDA	−3	−1	4	0	2	−6	−3	−10	−0	9	16	10	37	48	33	−6	−83	22

US$ millions unless shown otherwise. Fiscal quarters.

Staar Surgical Co: income statement, quarterly
Quarter	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Jan 2026	2026 Q1Apr 2026	2026 Q2Jul 2026
Revenue	89	49	43	44	95	58	94	94
Cost of revenue	20	17	15	12	17	14	25	24
Gross profit	68	32	28	33	78	44	69	70
Research and development	12	10	11	10	9	9	10	10
Selling, general and administrative	63	60	85	63	59	67	61	60
Operating income	6	−28	−57	−30	18	−23	8	10
Income before tax	13	−30	−54	−26	19	−21	8	11
Income tax	3	4	−0	−9	10	−2	3	3
Net income	10	−34	−54	−17	9	−18	5	8
Diluted EPS	$0.20	−$0.69	−$1.10	−$0.34	$0.18	−$0.36	$0.10	$0.16
EBITDA	7	−26	−55	−28	20	−21	10	12

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: PRCT vs STAA INGN vs STAA ANGO vs STAA STAA vs TCMD

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Staar Surgical Co's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Staar Surgical Co.